GLAXOSMITHKLINE PLC Form 6-K February 20, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 20 February 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Shares sold to meet tax liabilities

Following the vesting of awards granted in 2015 under the GlaxoSmithKline 2009 Performance Share Plan on 15 February 2018 and as notified on 16 February 2018, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.

Transaction notification

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms E Walmsley
- b) Position/statusc) Initial notification/c) Initial notification/c) Initial notification
- amendment Details of the issuer, emission allowance market participant, auction
- 2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

b)	Nature of the transaction

c)	Price(s) and volume(s)	Price(s) £13.0726	Volume(s) 65,247
d)	Aggregated information Aggregated volume Price	n/a (single tr	ansaction)
	Date of the transaction	2018-02-16	
f)	Place of the transaction	London Stoc (XLON)	k Exchange

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R G Connor	
b)	Position/status	President, Global Manufacturing and Supply	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
Ζ.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each	
	place where transaction(s) has been conducted		
		Ordinary shares of 25 pence	
		each ('Ordinary Shares')	

ISIN: GB0009252882

a) Description of the financial instrument

		The sale of Ordinary Shares
1 \		to meet tax liabilities for the
	Notes of the two sections	vesting of awards granted in
		2015 under the Company's
D)	Nature of the transaction	2009 Performance Share
		Plan.

()	Price(s) and volume(s)	Price(s)	Volume(s)
C)	Flice(s) and volume(s)	£13.0726	33,446
d)	Aggregated information Aggregated volume Price	n/a (single tra	ansaction)
u)		in a (oingre a ansaetton)	
e)	Date of the transaction	2018-02-16	
f)	Place of the transaction	London Stoc	k Exchange
1)		(XLON)	

1.	Details of PDMR/person closely associat	ted with them ('PCA')
a)	Name	Mr N Hirons
<b>b</b> )	Position/status	SVP, Global Ethics &
0)		Compliance
c)	Initial notification/	Initial notification
()	amendment	initial notification
2.	Details of the issuer, emission allowance	market participant, auction
2.	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b	e repeated for (i) each type of

instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £13.0726 16,216
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction Place of the transaction	2018-02-16 London Stock Exchange
0		Longon Stock Excitalize

f)	Place of the transaction	London Stock Exchange
		(XLON)

1.	Details of PDMR/	person closely assoc	iated with them ('PCA')
----	------------------	----------------------	-------------------------

a)	Name	Mr B McNamara
b)	Position/status	CEO, Consumer Healthcare
$(\mathbf{a})$	Initial notification/	Initial notification
C)	amendment	initial nouncation

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) NameGlaxoSmithKline plcb) LEI5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc

American Depositary Shares ('ADSs') ISIN: US37733W1053

	The sale of ADSs to meet tax
	liabilities further to the
	vesting of awards granted in
b) Nature of the transaction	2015 under the Company's
b) Nature of the transaction	2009 Performance Share
	Plan.

c)	Price(s) and volume(s)	Price(s) \$37.4803	Volume(s) 14,389
d)	Aggregated information Aggregated volume Price	n/a (single tr	ansaction)
e) f)	Date of the transaction Place of the transaction	2018-02-16 New York St (XNYS)	ock Exchange

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr D S Redfern	
b)	Position/status	Chief Strategy Officer	
c)	Initial notification/	Initial notification	
	amendment		
2	Details of the issuer, emission allowance	e market participant, auction	

<sup>2</sup>. platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction (a), contian to h	a manager of fam (i) as all trues of

- Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
  - place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s) Volume(s) £13.0726 26,605

d)	Aggregated information	n/a (single transaction)
u)	Aggregated volume Price	
e)	Date of the transaction	2018-02-16
f)	Place of the transaction	London Stock Exchange
1)		(XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
- Ms C Thomas a) Name
- b) Position/status SVP, Human Resources Initial notification/ c) Initial notification amendment
- Details of the issuer, emission allowance market participant, auction
- 2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

b) Nature of the transaction

c)	Price(s) and volume(s)	Price(s) £13.0726	Volume(s) 35,473
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2018-02-16	
f)	Place of the transaction	London Stock Exchange	
		(XLON)	

1.	Details of PDMR/person	closely associated with them ('PCA')	
a)	Name	Mr P C Thomson	

Mr P C Thomson

- b) Position/status
- c) Initial notification/

SVP, Communications & Government Affairs Initial notification

amendment

- 2. Details of the issuer, emission allowance market participant, auction
- <sup>2</sup>. platform, auctioneer or auction monitor
- a) Nameb) LEI

GlaxoSmithKline plc

- 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

b) Nature of the transaction

c) Price(s) and volume(s)	Price(s) Volume(s) £13.0726 20,524
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-02-16
f) Place of the transaction	London Stock Exchange (XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D E Troy
  b) Position/status SVP & General Counsel
  c) Initial notification/ amendment Initial notification
   betails of the issuer, emission allowance market participant, auction
- 2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
  b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
   3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
   a) Description of the financial instrument GlaxoSmithKline plc

American Depositary Shares ('ADSs') ISIN: US37733W1053

b)	Nature of the transaction	The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s) \$37.4803 31,635	
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2018-02-16	
f)	Place of the transaction	New York Stock Exchange (XNYS)	
1.	Details of PDMR/person closely associa	ted with them ('PCA')	
	Name	Dr P J T Vallance	
	Position/status	President, R&D	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b		
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
	Place where transaction(s) has been conc		

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's

# 2009 Performance Share Plan.

c) Price(s) and volume(s) $\pounds 13.0726  73,$ d) Aggregated information n/a (single transaction)	lume(s) 783 ction)		
e) Date of the transaction 2018-02-16 Place of the transaction L ondon Stock Fx	change		
f) Thee of the transaction (XLON)	ienange		
. Details of PDMR/person closely associated with them ('PCA')			
a) Name Mrs V A Whyte	Mrs V A Whyte		
b) Position/status Company Secreta	Company Secretary		
c) Initial notification/ amendment Initial notification	Initial notification		
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a) Name GlaxoSmithKline	e nlc		
·	5493000HZTVUYLO1D793		
Details of the transaction(s): section to be repeated for (i) e	12012//0		
3. instrument; (ii) each type of transaction; (iii) each date; and	• •		
place where transaction(s) has been conducted			
Ordinary shares of	of 25 pence		
each ('Ordinary S	- r		
	Shares')		

a) Description of the financial instrument

b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£13.0726	4,544
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2018-02-16	
f)	Place of the transaction	London Stock Exchange	
		(XLON)	

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: February 20, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc